Resultados de procura - David I. Marks

Limitar resultados
  1. 1
    Management of adults with T-cell lymphoblastic leukemia

    Management of adults with T-cell lymphoblastic leukemia por David I. Marks, Clare Rowntree

    Publicado 2017
    Ligazón do recurso Ligazón do recurso
    Revisão
    Engadir a favoritos
    Gardado en:
  2. 2
    Patient‐reported outcomes from a phase 3 randomized controlled trial of inotuzumab ozogamicin versus standard therapy for relapsed/refractory acute lymphoblastic leukemia

    Patient‐reported outcomes from a phase 3 randomized controlled trial of inotuzumab ozogamicin versus standard therapy for relapsed/refractory acute lymphoblastic leukemia por Hagop M. Kantarjian, Yun Su, Elias Jabbour, Helen Bhattacharyya, Eric Yan, Joseph C. Cappelleri, David I. Marks

    Publicado 2018
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  3. 3
    Diagnosis of invasive aspergillosis in bone marrow transplant recipients by polymerase chain reaction

    Diagnosis of invasive aspergillosis in bone marrow transplant recipients by polymerase chain reaction por Emma Williamson, John P. Leeming, Helen Palmer, Colin G. Steward, David W. Warnock, David I. Marks, Michael Millar

    Publicado 2000
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  4. 4
    The Solution Structure of a Transient Photoreceptor Intermediate: Δ25 Photoactive Yellow Protein

    The Solution Structure of a Transient Photoreceptor Intermediate: Δ25 Photoactive Yellow Protein por Cédric Bernard, Klaartje Houben, Nocky M. Derix, David I. Marks, Michael Horst, Klaas J. Hellingwerf, Rolf Boelens, Robert Kaptein, Nico A. J. van Nuland

    Publicado 2005
    Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  5. 5
    Management of important adverse events associated with inotuzumab ozogamicin: expert panel review

    Management of important adverse events associated with inotuzumab ozogamicin: expert panel review por Partow Kebriaei, Corey Cutler, Marcos de Lima, Sergio Giralt, Stephanie J. Lee, David I. Marks, Akil Merchant, Wendy Stock, Koen van Besien, Matthias Stelljes

    Publicado 2018
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  6. 6
    Voriconazole versus itraconazole for antifungal prophylaxis following allogeneic haematopoietic stem‐cell transplantation

    Voriconazole versus itraconazole for antifungal prophylaxis following allogeneic haematopoietic stem‐cell transplantation por David I. Marks, Antonio Pagliuca, Christopher C. Kibbler, Axel Glasmacher, Claus Peter Heußel, Michal Kantecki, Paul Miller, Patricia Ribaud, Haran T. Schlamm, Carlos Solano, Gordon Cook

    Publicado 2011
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  7. 7
    Conditioning Chemotherapy Dose Adjustment in Obese Patients: A Review and Position Statement by the American Society for Blood and Marrow Transplantation Practice Guideline Committee

    Conditioning Chemotherapy Dose Adjustment in Obese Patients: A Review and Position Statement by the American Society for Blood and Marrow Transplantation Practice Guideline Committ... por Joseph Bubalo, Paul A. Carpenter, Navneet S. Majhail, Miguel‐Angel Perales, David I. Marks, Paul Shaughnessy, Joseph Pidala, Helen Leather, John R. Wingard, Bipin N. Savani

    Publicado 2014
    Ligazón do recurso Ligazón do recurso
    Revisão
    Engadir a favoritos
    Gardado en:
  8. 8
    The clinical features, risk factors and outcome of thrombotic thrombocytopenic purpura occurring after bone marrow transplantation

    The clinical features, risk factors and outcome of thrombotic thrombocytopenic purpura occurring after bone marrow transplantation por Rhian Fuge, Jennifer M. Bird, Anne Fraser, Dan Hart, Linda Hunt, Jacqueline Cornish, Nicholas Goulden, A Oakhill, Derwood Pamphilon, Colin G. Steward, David I. Marks

    Publicado 2001
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  9. 9
    Outcome following Reduced-Intensity Allogeneic Stem Cell Transplantation (RIC AlloSCT) for Relapsed and Refractory Mantle Cell Lymphoma (MCL): A Study of the British Society for Blood and Marrow Transplantation

    Outcome following Reduced-Intensity Allogeneic Stem Cell Transplantation (RIC AlloSCT) for Relapsed and Refractory Mantle Cell Lymphoma (MCL): A Study of the British Society for Bl... por Gordon Cook, Graeme Smith, Keiren Kirkland, Jungwha Lee, Rachel Pearce, Kirsty Thomson, Emma Morris, Kim Orchard, Simon Rule, Nigel H. Russell, Charles Craddock, David I. Marks

    Publicado 2010
    Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  10. 10
    Results of alemtuzumab-based reduced-intensity allogeneic transplantation for chronic lymphocytic leukemia: a British Society of Blood and Marrow Transplantation Study

    Results of alemtuzumab-based reduced-intensity allogeneic transplantation for chronic lymphocytic leukemia: a British Society of Blood and Marrow Transplantation Study por Julio Delgado, Kirsty Thomson, Nigel H. Russell, Joanne Ewing, Wendy A. Stewart, Gordon Cook, Stephen Devereux, Richard Lovell, Rajesh Chopra, David I. Marks, Stephen Mackinnon, Donald Milligan

    Publicado 2005
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  11. 11
    Factors Influencing the Outcome of a Second Autologous Stem Cell Transplant (ASCT) in Relapsed Multiple Myeloma: A Study from the British Society of Blood and Marrow Transplantation Registry

    Factors Influencing the Outcome of a Second Autologous Stem Cell Transplant (ASCT) in Relapsed Multiple Myeloma: A Study from the British Society of Blood and Marrow Transplantatio... por Gordon Cook, Effie Liakopoulou, Rachel Pearce, Jim Cavet, Gareth J. Morgan, Keiren Kirkland, Julia Lee, Faith E. Davies, R. Hall, Amin Rahemtulla, Nigel H. Russell, David I. Marks

    Publicado 2011
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  12. 12
    Reduced cellularity of bone marrow in multiple sclerosis with decreased MSC expansion potential and premature ageing in vitro

    Reduced cellularity of bone marrow in multiple sclerosis with decreased MSC expansion potential and premature ageing in vitro por Juliana Redondo, Pamela Sarkar, Kevin Kemp, Paul Virgo, Joya Pawade, Aimie Norton, David C. Emery, M.G. Guttridge, David I. Marks, Alastair Wilkins, Neil Scolding, Claire M Rice

    Publicado 2017
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  13. 13
    A Phase 3 Randomized Study of Remestemcel-L versus Placebo Added to Second-Line Therapy in Patients with Steroid-Refractory Acute Graft-versus-Host Disease

    A Phase 3 Randomized Study of Remestemcel-L versus Placebo Added to Second-Line Therapy in Patients with Steroid-Refractory Acute Graft-versus-Host Disease por Partow Kebriaei, Jack Hayes, Andrew Daly, Joseph P. Uberti, David I. Marks, Robert J. Soiffer, Edmund K. Waller, Elizabeth Burke, Donna Skerrett, Elizabeth J. Shpall, Paul J. Martin

    Publicado 2019
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  14. 14
    Younger Matched Unrelated Donors Confer Decreased Relapse Risk Compared to Older Sibling Donors in Older Patients with B Cell Acute Lymphoblastic Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation

    Younger Matched Unrelated Donors Confer Decreased Relapse Risk Compared to Older Sibling Donors in Older Patients with B Cell Acute Lymphoblastic Leukemia Undergoing Allogeneic Hem... por Muhammad Bilal Abid, Noel Estrada-Merly, Mei‐Jie Zhang, Karen Chen, Christopher Bredeson, David Allan, Mitchell Sabloff, David I. Marks, Mark R. Litzow, Christopher S. Hourigan, Partow Kebriaei, Wael Saber

    Publicado 2023
    Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  15. 15
    Alemtuzumab with fludarabine and cyclophosphamide reduces chronic graft-versus-host disease after allogeneic stem cell transplantation for acquired aplastic anemia

    Alemtuzumab with fludarabine and cyclophosphamide reduces chronic graft-versus-host disease after allogeneic stem cell transplantation for acquired aplastic anemia por Judith Marsh, Vikas Gupta, ZiYi Lim, Aloysius Ho, Robin Ireland, Janet Hayden, Victoria Potter, Mickey Koh, M. Serajul Islam, Nigel H. Russell, David I. Marks, Ghulam J. Mufti, Antonio Pagliuca

    Publicado 2011
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  16. 16
    Inotuzumab ozogamicin for relapsed/refractory acute lymphoblastic leukemia: outcomes by disease burden

    Inotuzumab ozogamicin for relapsed/refractory acute lymphoblastic leukemia: outcomes by disease burden por Daniel J. DeAngelo, Anjali S. Advani, David I. Marks, Matthias Stelljes, Michaela Liedtke, Wendy Stock, Nicola Gökbuget, Elias Jabbour, Akil Merchant, Tao Wang, Erik Vandendries, Alexander Neuhof, Hagop M. Kantarjian, Susan O’Brien

    Publicado 2020
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  17. 17
    Outcomes of Allogeneic Stem Cell Transplantation after Inotuzumab Ozogamicin Treatment for Relapsed or Refractory Acute Lymphoblastic Leukemia

    Outcomes of Allogeneic Stem Cell Transplantation after Inotuzumab Ozogamicin Treatment for Relapsed or Refractory Acute Lymphoblastic Leukemia por David I. Marks, Partow Kebriaei, Matthias Stelljes, Nicola Gökbuget, Hagop M. Kantarjian, Anjali S. Advani, Akil Merchant, Wendy Stock, Ryan D. Cassaday, Tao Wang, Hui Zhang, Fausto R. Loberiza, Erik Vandendries, Daniel J. DeAngelo

    Publicado 2019
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  18. 18
    Outcomes in older adults with acute lymphoblastic leukaemia (<scp>ALL</scp>): results from the international <scp>MRC UKALL XII</scp>/<scp>ECOG</scp>2993 trial

    Outcomes in older adults with acute lymphoblastic leukaemia (<scp>ALL</scp>): results from the international <scp>MRC UKALL XII</scp>/<scp>ECOG</scp>2993 trial por Jonathan Sive, Georgina Buck, Adele K. Fielding, Hillard M. Lazarus, Mark R. Litzow, Selina M. Luger, David I. Marks, Andrew McMillan, Anthony V. Moorman, Susan Richards, Jacob M. Rowe, Martin S. Tallman, Anthony H. Goldstone

    Publicado 2012
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  19. 19
    Systematic review and mixed treatment comparison meta-analysis of randomized clinical trials of primary oral antifungal prophylaxis in allogeneic hematopoietic cell transplant recipients

    Systematic review and mixed treatment comparison meta-analysis of randomized clinical trials of primary oral antifungal prophylaxis in allogeneic hematopoietic cell transplant reci... por Eric J. Bow, David J. Vanness, Monica A. Slavin, Catherine Cordonnier, Oliver A. Cornely, David I. Marks, Antonio Pagliuca, Carlos Solano, Lael Cragin, A. Shaul, Sonja Sorensen, Richard Chambers, Michal Kantecki, David Weinstein, Haran T. Schlamm

    Publicado 2015
    Ligazón do recurso Ligazón do recurso
    Revisão
    Engadir a favoritos
    Gardado en:
  20. 20
    Impact of immune modulation with anti–T-cell antibodies on the outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies

    Impact of immune modulation with anti–T-cell antibodies on the outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies por Robert J. Soiffer, Jennifer Le‐Rademacher, Vincent T. Ho, Fangyu Kan, Andrew Artz, Richard E. Champlin, Steven M. Devine, Luis Isola, Hillard M. Lazarus, David I. Marks, David Porter, Edmund K. Waller, Mary M. Horowitz, Mary Eapen

    Publicado 2011
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:

Ferramentas de procura: